3 research outputs found
A high activity index of stearoyl-CoA desaturase is associated with increased risk of fracture in men
Recommended from our members
Markers of imminent myocardial infarction
Acknowledgements: Transnational access to the large European prospective cohorts was provided by the BBMRI-LPC project funded by the European Commission’s Seventh Framework Programme (grant no. 313010, J.S.). The Estonian Biobank study was supported by the European Union through the European Regional Development Fund (project no. 2014-2020.4.01.15-0012) and by institutional research funding IUT (IUT20-60) of the Estonian Ministry of Education and Research. We thank M. Alver (Estonian Biobank) for help with phenotype data. The Trøndelag Health Study (HUNT) is a collaboration between the HUNT Research Centre (Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, NTNU), Trøndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. The Lifelines initiative was made possible by a subsidy from the Dutch Ministry of Health, Welfare and Sport; the Dutch Ministry of Economic Affairs; the University Medical Center Groningen (UMCG), Groningen University; and the provinces in the north of the Netherlands (Drenthe, Friesland, Groningen). Lifelines is a multidisciplinary, prospective, population-based cohort study examining the health and health-related behaviors of 167,729 persons living in the north of the Netherlands in a unique three-generation design. The study used a broad range of investigative procedures in assessing the biomedical, sociodemographic, behavioral, physical and psychological factors that contribute to the health and disease of the general population, with a particular focus on multimorbidity and complex genetics. EPIC-CVD was supported by funding from the European Commission Framework Programme 7 (HEALTH-F2-2012-279233), European Research Council (268834), Novartis, UK Medical Research Council (G0800270, MR/L003120/1), British Heart Foundation (SP/09/002, RG/13/13/30194, RG/18/13/33946), and National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The coordination of EPIC was financially supported by the International Agency for Research on Cancer (IARC) and the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts were supported by the Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle GĂ©nĂ©rale de l’Education Nationale, Institut National de la SantĂ© et de la Recherche MĂ©dicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro (AIRC), Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (Netherlands); Health Research Fund (FIS)–Instituto de Salud Carlos III (ISCIII), regional governments (AndalucĂa, Asturias, Basque Country, Murcia and Navarra), Catalan Institute of Oncology (ICO) (Spain); Swedish Cancer Society, Swedish Research Council and county councils of SkĂĄne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk, C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom). We thank all EPIC participants and staff for their contribution to the study, the laboratory teams at the Medical Research Council Epidemiology Unit for sample management and at Cambridge Genomic Services for genotyping, S. Spackman for data management, and the team at the EPIC-CVD Coordinating Centre for study coordination and administration. SCAPIS was supported by Hjärt-Lungfonden, the Knut and Alice Wallenberg Foundation, the Swedish Research Council and VINNOVA. This research was conducted using the UK Biobank resource under application no. 52678. Grants were received from the European Research Council (no. 801965), Swedish Research Council, VR (2019-01471) and Hjärt-Lungfonden (20190505) (T.F.). Grants were received from AFA Försäkring (160266), the Swedish Research Council (2016-01065), Hjärt-Lungfonden (20160734) and A. Wiklöf (J.S.). The computations were enabled by resources in projects sens2019006 and sens2020005 provided by the Swedish National Infrastructure for Computing (SNIC) at UPPMAX, partially funded by the Swedish Research Council through grant agreement no. 2018-05973. The funding sources for the different cohorts and the sponsors of the current work did not have any part in the collection, analysis and interpretation of data or in the decision to submit the paper for publication. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article, and they do not necessarily represent the decisions, policies or views of the International Agency for Research on Cancer/World Health Organization.AbstractMyocardial infarction is a leading cause of death globally but is notoriously difficult to predict. We aimed to identify biomarkers of an imminent first myocardial infarction and design relevant prediction models. Here, we constructed a new case–cohort consortium of 2,018 persons without prior cardiovascular disease from six European cohorts, among whom 420 developed a first myocardial infarction within 6 months after the baseline blood draw. We analyzed 817 proteins and 1,025 metabolites in biobanked blood and 16 clinical variables. Forty-eight proteins, 43 metabolites, age, sex and systolic blood pressure were associated with the risk of an imminent first myocardial infarction. Brain natriuretic peptide was most consistently associated with the risk of imminent myocardial infarction. Using clinically readily available variables, we devised a prediction model for an imminent first myocardial infarction for clinical use in the general population, with good discriminatory performance and potential for motivating primary prevention efforts.</jats:p